Results 91 to 100 of about 1,481 (180)

Setting of initiation and factors associated with antidepressant use on entry to long‐term care facilities

British Journal of Clinical Pharmacology, Volume 91, Issue 6, Page 1749-1759, June 2025.
Abstract Aims Antidepressant use increases around long‐term care facility (LTCF) entry, and initiation during hospitalizations may contribute to this. This study characterized the care setting (i.e., community‐based, hospital or LTCF) where antidepressants were initiated and determined associated resident characteristics.
Georgina A. Hughes, Maria C. Inacio, Debra Rowett, Catherine Lang, Robert N. Jorissen, Megan Corlis, Janet K. Sluggett   +6 more
wiley   +1 more source

Psychedelic Drugs in Mental Disorders: Current Clinical Scope and Deep Learning‐Based Advanced Perspectives

Advanced Science, Volume 12, Issue 15, April 17, 2025.
Graphic illustration showing the strategic approaches based on the currently investigated evidence of psychedelics that suggests the challenges and how to address the prescription of mental disorders. These applicable avenues may provide substantial insight into distinguishing between brain networks and psychedelics.
Sung‐Hyun Kim, Sumin Yang, Jeehye Jung, Jeonghyeon Choi, Mingon Kang, Jae‐Yeol Joo   +5 more
wiley   +1 more source

Safety Profile and Suicidality Associated with the Use of Esketamine in the Treatment of Major Depressive Disorder in European Countries: An EudraVigilance Database Analysis

Pharmaceuticals
Background/Objective: Major depressive disorder (MDD) is a common mental disorder, with a significant portion of patients developing treatment-resistant depression (TRD).
Ilaria Ammendolia, Carmen Mannucci, Emanuela Esposito, Gioacchino Calapai, Mariaconcetta Currò, Paola Midiri, Cristina Mondello, Luigi Cardia, Fabrizio Calapai   +8 more
doaj   +1 more source

Ketamine and Esketamine in Clinical Trials: FDA‐Approved and Emerging Indications, Trial Trends With Putative Mechanistic Explanations

Clinical Pharmacology &Therapeutics, Volume 117, Issue 2, Page 374-386, February 2025.
Ketamine has a long and very eventful pharmacological history. Its enantiomer, esketamine ((S)‐ketamine), was approved by the US Food and Drug Administration (FDA) and EMA for patients with treatment‐resistant depression (TRD) in 2019. The number of approved indications for ketamine and esketamine continues to increase, as well as the number of ...
Ksenia A. Vekhova, Eugenia D. Namiot, Jörgen Jonsson, Helgi B. Schiöth   +3 more
wiley   +1 more source

How Do People Who Undergo Ketamine Treatment for a Psychiatric Problem Subjectively Experience This Intervention? A Meta‐Synthesis of Qualitative Studies

International Journal of Mental Health Nursing, Volume 34, Issue 1, February 2025.
ABSTRACT Ketamine treatment has shown promising effects for different mental disorders. Yet, little is known on how people who receive ketamine for a psychiatric problem subjectively experience undergoing this intervention. We conducted a systematic literature search to identify relevant qualitative research on the first‐person experience of undergoing
Melanie Trimmel, Antonia Renner, Alexander Kaltenboeck   +2 more
wiley   +1 more source

Oral esketamine for patients with severe treatment-resistant depression:Effectiveness, safety, and tolerability of a six-week open-label treatment program [PDF]

Background: Oral esketamine for patients with treatment-resistant depression (TRD) could offer certain advantages over other routes, such as intravenous or intranasal, but it has not been systematically studied in a real-world setting.
Kamphuis, Jeanine, Schoevers, Robert A., Smith-Apeldoorn, Sanne Y., Spijker, Jan, van der Meij, Annemarie, Veraart, Jolien K.E.   +5 more
core   +1 more source

Esketamine Provides Neuroprotection After Intracerebral Hemorrhage in Mice via the NTF3/PI3K/AKT Pathway

CNS Neuroscience &Therapeutics, Volume 30, Issue 12, December 2024.
Schematic representation of the underlying molecular mechanisms by which ESK mediates neuroprotection of the PI3K/AKT signaling pathway in mice with ICH through activation of NTF3 expression. ABSTRACT Background Esketamine (ESK), a noncompetitive antagonist of N‐methyl‐D‐aspartate (NMDA) receptors, modulates neurotransmitter signaling in the central ...
Xiaoyu Niu, Yuanyuan Zheng, Wang Wang, Liwei Zhang, Shaoshuai Wang, Xihua Lu, Junyang Wang, Gaiqing Yang, Ting Zhao, Qiang Li, Nan Li, Junmin Wang, Jian Wang, Changsheng Li   +13 more
wiley   +1 more source

Ginsenoside Rg1: A Neuroprotective Natural Dammarane‐Type Triterpenoid Saponin With Anti‐Depressive Properties

CNS Neuroscience &Therapeutics, Volume 30, Issue 12, December 2024.
Rg1 exhibits antidepressant effects through diverse mechanisms, such as anti‐inflammation, synaptic protection, neurogenesis promotion, brain‐derived neurotrophic factor release, enhancement of astrocyte gap junction function, and regulation of hypothalamic–pituitary–adrenal axis and antioxidative stress. Experimental studies validate Rg1's efficacy in
Dong Han, Zheng Zhao, Tinghui Mao, Man Gao, Xue Yang, Yan Gao   +5 more
wiley   +1 more source

Effect of Concomitant Benzodiazepine Use on Efficacy and Safety of Esketamine Nasal Spray in Patients with Major Depressive Disorder and Acute Suicidal Ideation or Behavior: Pooled Randomized, Controlled Trials

Neuropsychiatric Disease and Treatment, 2021
Bettina Diekamp,1 Stephane Borentain,2 Dong-Jing Fu,3 Robert Murray,4 Kristin Heerlein,1 Qiaoyi Zhang,5 Cornelius Schüle,6 Maju Mathews2 1Department of Medical and Scientific Affairs, Janssen-Cilag GmbH, Neuss, Germany; 2Department of Global Medical ...
Diekamp B, Borentain S, Fu DJ, Murray R, Heerlein K, Zhang Q, Schüle C, Mathews M   +7 more
doaj  

Ketamine for the treatment of major depression: a systematic review and meta-analysis

, 2023
Background: Intranasal esketamine has received regulatory approvals for the treatment of depression. Recently a large trial of repeated dose racemic ketamine also demonstrated efficacy in severe depression.
Bahji, A, Loo, C , Nikolin, S , Rodgers, A , Schwaab, A, Vazquez, G, Zarate, C   +6 more
core   +1 more source